Your browser is no longer supported. Please, upgrade your browser.
CARA Cara Therapeutics, Inc. daily Stock Chart
Cara Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.51 Insider Own2.50% Shs Outstand46.80M Perf Week8.31%
Market Cap651.02M Forward P/E- EPS next Y-2.36 Insider Trans-5.75% Shs Float42.96M Perf Month5.02%
Income-115.40M PEG- EPS next Q-0.59 Inst Own71.90% Short Float10.25% Perf Quarter-15.81%
Sales24.00M P/S27.13 EPS this Y-20.90% Inst Trans0.57% Short Ratio11.80 Perf Half Y-5.41%
Book/sh3.01 P/B4.94 EPS next Y0.40% ROA-53.60% Target Price- Perf Year-23.58%
Cash/sh2.97 P/C5.00 EPS next 5Y- ROE-66.00% 52W Range8.88 - 26.67 Perf YTD-7.76%
Dividend- P/FCF- EPS past 5Y-24.10% ROI-59.40% 52W High-44.28% Beta1.78
Dividend %- Quick Ratio5.70 Sales past 5Y44.30% Gross Margin- 52W Low67.34% ATR0.61
Employees67 Current Ratio5.70 Sales Q/Q7.70% Oper. Margin- RSI (14)59.01 Volatility5.56% 4.24%
OptionableYes Debt/Eq0.00 EPS Q/Q7.10% Profit Margin- Rel Volume2.42 Prev Close13.93
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume373.22K Price14.86
Recom1.70 SMA2010.46% SMA500.36% SMA200-3.57% Volume903,882 Change6.68%
Apr-21-20Reiterated H.C. Wainwright Buy $30 → $33
Aug-12-19Reiterated H.C. Wainwright Buy $31 → $30
May-29-19Reiterated Laidlaw Buy $26 → $32
Feb-06-19Resumed Jefferies Buy $22
Jan-15-19Initiated BofA/Merrill Neutral $19
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-13-18Initiated Jefferies Buy $30
Aug-08-18Reiterated Stifel Buy $22 → $26
Jun-28-18Reiterated H.C. Wainwright Buy $24 → $26
Mar-12-18Resumed H.C. Wainwright Buy $22
Feb-12-18Upgrade Janney Neutral → Buy
Jan-19-18Initiated Seaport Global Securities Buy $27
Jun-30-17Reiterated Stifel Buy $24 → $20
Jun-30-17Reiterated Laidlaw Buy $35 → $30
Jun-30-17Downgrade Janney Buy → Neutral
Mar-28-17Reiterated Laidlaw Buy $20 → $35
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Mar-10-17Reiterated Laidlaw Buy $17 → $20
Oct-13-16Initiated H.C. Wainwright Buy $20
Aug-08-16Reiterated Needham Buy $27 → $23
Oct-20-20 03:30PM  
Oct-16-20 11:01AM  
Oct-14-20 12:57PM  
Oct-11-20 08:55AM  
Oct-01-20 07:00AM  
Aug-27-20 03:37PM  
Aug-11-20 05:30PM  
Aug-10-20 06:05PM  
Aug-06-20 04:01PM  
Aug-03-20 04:01PM  
Jul-29-20 12:33PM  
Jul-13-20 02:47PM  
Jul-08-20 01:34PM  
Jun-30-20 07:00AM  
Jun-25-20 06:04PM  
Jun-17-20 07:00AM  
May-27-20 04:01PM  
May-15-20 11:00AM  
May-12-20 06:00AM  
May-11-20 05:55PM  
May-07-20 07:00AM  
May-04-20 04:01PM  
Apr-29-20 07:14AM  
Apr-28-20 12:34PM  
Apr-21-20 08:07AM  
Apr-20-20 09:40AM  
Apr-08-20 07:00AM  
Mar-25-20 07:00AM  
Mar-23-20 06:49AM  
Mar-10-20 01:45PM  
Feb-29-20 08:05AM  
Feb-27-20 05:55PM  
Feb-20-20 04:01PM  
Feb-03-20 06:12AM  
Jan-15-20 05:26PM  
Jan-08-20 04:01PM  
Dec-19-19 09:32PM  
Dec-06-19 04:01PM  
Dec-04-19 10:02AM  
Dec-03-19 04:01PM  
Nov-13-19 09:12AM  
Nov-12-19 04:01PM  
Nov-11-19 07:00AM  
Nov-05-19 06:35PM  
Nov-01-19 07:00AM  
Oct-29-19 04:40PM  
Oct-20-19 08:45AM  
Oct-14-19 07:00AM  
Oct-01-19 02:23PM  
Sep-26-19 04:01PM  
Sep-19-19 10:11AM  
Aug-21-19 04:24PM  
Aug-19-19 12:34PM  
Aug-14-19 10:54AM  
Aug-05-19 10:21AM  
Jul-31-19 04:01PM  
Jul-29-19 04:01PM  
Jul-26-19 09:18PM  
Jul-25-19 11:59AM  
Jul-24-19 08:42PM  
Jul-22-19 07:00AM  
Jul-17-19 07:15PM  
Jul-16-19 10:28AM  
Jul-14-19 07:30AM  
Jul-13-19 07:56AM  
Jul-12-19 06:27PM  
Jul-11-19 08:30AM  
Jul-09-19 07:00AM  
Jul-02-19 07:16AM  
Jun-26-19 07:00AM  
Jun-13-19 07:04PM  
Jun-02-19 09:09AM  
Jun-01-19 10:17AM  
May-31-19 07:00AM  
May-30-19 07:48AM  
May-29-19 02:30PM  
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHALMERS DEREK TPresident & CEOSep 03Sale16.003,20151,216953,220Sep 08 05:22 PM
CHALMERS DEREK TPresident & CEOAug 03Sale16.425,00082,100956,421Aug 05 06:20 PM
CHALMERS DEREK TPresident & CEOJul 01Sale17.115,00085,550961,421Jul 02 04:40 PM
Goncalves JoanaChief Medical OfficerJun 12Sale15.2010,627161,53035,373Jun 12 06:00 PM
CHALMERS DEREK TPresident & CEOJun 03Sale16.014,30068,843966,421Jun 03 07:53 PM
Ives Jeffrey L.DirectorJun 01Option Exercise9.941,0009,9407,000Jun 03 07:51 PM
CHALMERS DEREK TPresident & CEOJun 01Sale16.0070011,200970,721Jun 03 07:53 PM
Ives Jeffrey L.DirectorJun 01Sale16.001,00016,0006,000Jun 03 07:51 PM
CHALMERS DEREK TPresident & CEOMay 22Sale16.003715,936971,421May 22 06:26 PM
CHALMERS DEREK TPresident & CEOMay 21Sale16.003,50056,000971,792May 22 06:26 PM
CHALMERS DEREK TPresident & CEOMay 20Sale16.001,20019,200975,292May 22 06:26 PM
Ives Jeffrey L.DirectorMay 12Option Exercise9.942,50024,8508,500May 14 08:02 PM
CHALMERS DEREK TPresident & CEOMay 12Sale16.004,92978,864976,492May 14 08:04 PM
Ives Jeffrey L.DirectorMay 12Sale16.002,50040,0006,000May 14 08:02 PM
Ives Jeffrey L.DirectorApr 21Option Exercise9.942,50024,8508,500Apr 21 07:09 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Apr 21Sale15.562,72142,33938,382Apr 21 06:50 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DApr 21Sale15.5812,894200,889104,492Apr 21 06:49 PM
CHALMERS DEREK TPresident & CEOApr 21Sale15.566,34898,775981,421Apr 21 06:47 PM
Ives Jeffrey L.DirectorApr 21Sale16.002,50040,0006,000Apr 21 07:09 PM
Ives Jeffrey L.DirectorMar 04Option Exercise9.942,50024,8508,500Mar 06 04:39 PM
Ives Jeffrey L.DirectorMar 04Sale16.002,50040,0006,000Mar 06 04:39 PM
Ives Jeffrey L.DirectorFeb 03Option Exercise9.942,50024,8508,500Feb 05 05:01 PM
Ives Jeffrey L.DirectorFeb 03Sale16.232,50040,5756,000Feb 05 05:01 PM
Ives Jeffrey L.DirectorJan 02Option Exercise9.942,50024,8508,500Jan 06 06:06 PM
Ives Jeffrey L.DirectorJan 02Sale16.132,50040,3256,000Jan 06 06:06 PM
CHALMERS DEREK TPresident & CEOJan 02Sale16.0510,000160,500917,769Jan 06 06:05 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Dec 04Sale17.053,98067,85916,769Dec 04 07:52 PM
Mohindru ManiCFO & Chief Strategy OfficerDec 04Sale17.054,75581,07317,441Dec 04 07:50 PM
CHALMERS DEREK TPresident & CEODec 04Sale17.0510,699182,418927,769Dec 04 07:47 PM
Ives Jeffrey L.DirectorDec 02Option Exercise5.322,50013,3008,500Dec 04 07:49 PM
Ives Jeffrey L.DirectorDec 02Sale25.832,50064,5756,000Dec 04 07:49 PM
CHALMERS DEREK TPresident & CEODec 02Sale25.7910,000257,900918,468Dec 04 07:47 PM
Ives Jeffrey L.DirectorNov 01Option Exercise5.322,50013,3008,500Nov 05 06:21 PM
Ives Jeffrey L.DirectorNov 01Sale20.682,50051,7006,000Nov 05 06:21 PM
CHALMERS DEREK TPresident & CEONov 01Sale20.795,000103,950928,468Nov 05 06:07 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DOct 25Sale19.914,00079,64063,886Oct 29 08:36 PM